Biotech Values

[mcbio]

Re: ATI-7505

The latter: spin. If a product candidate has bona fide commercial potential, large companies such as PG generally find a way to get some value for it.

Fair enough Dew. I just checked the results for the Phase 2b trial of the drug after my prior post. The trial was cut short, since P&G dropped the drug. See: http://investors.aryx.com/releasedetail.cfm?ReleaseID=329629 .

ARYX reported statistical significance for the primary endpoint of improvement in the total number of spontaneous bowel movements, but it was at the 2nd highest dosing regimen of 80mg bid (apparently 120 mg bid was not successful). I'm generally leery when there's not a clear dose-dependent response; i.e., why wouldn't 120 mg bid be successful if 80mg bid was? That said, the 80mg bid results were apparently stat sig. What do you make of such a paradox?